US Patent Issued to ImmunEdge, The Board of Trustees of the Leland Stanford Junior University on Feb. 3 for "Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein" (California Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,189, issued on Feb. 3, was assigned to ImmunEdge Inc. (Redwood City, Calif.) and The Board of Trustees of the Leland Stanford Junior University (Stanford, Calif.).

"Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein" was invented by Bo Yu (Mountain View, Calif.), Edgar G. Engleman (Atherton, Calif.), Xiangyue Zhang (Sunnyvale, Calif.) and David Kung-Chun Chiu (Mountain View, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that sp...